Patents by Inventor Gao Liu

Gao Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8461306
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 11, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8445646
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8444980
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8436146
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Practical measurement-based session admission control for Wi-Fi LAN systems
    Patent number: 8385197
    Abstract: A communication system is provided that can control which communication sessions with mobile devices are admitted to a wireless access point. The admission decisions are based on actual measurements of radio frequency (RF) utilization. The RF utilization is determined on a per access class basis. Access classes may be defined by protocol but are, generally, voice, video and data. Thus, the system provides the ability to determine admissions that allows for the incorporation of factors including collisions, the distance from the access point to which a mobile device is communicating, and other factors.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: February 26, 2013
    Assignee: Avaya Inc.
    Inventors: Marvin Krym, Jozef Babiarz, Lambertus Verberk, Xiao-Gao Liu, Tarak Shingne
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8349330
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: January 8, 2013
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Biodegradable synthetic bone composites
    Patent number: 8344042
    Abstract: The invention provides for a biodegradable synthetic bone composition comprising a biodegradable hydrogel polymer scaffold comprising a plurality of hydrolytically unstable linkages, and an inorganic component; such as a biodegradable poly(hydroxyethylmethacrylate)/hydroxyapatite (pHEMA/HA) hydrogel composite possessing mineral content approximately that of human bone.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: January 1, 2013
    Assignee: The Regents of the University of California
    Inventors: Gao Liu, Dacheng Zhao, Eduardo Saiz, Antoni P. Tomsia
  • Organic light emitting diodes with structured electrodes
    Patent number: 8324651
    Abstract: A cathode that contain nanostructures that extend into the organic layer of an OLED has been described. The cathode can have an array of nanotubes or a layer of nanoclusters extending out from its surface. In another arrangement, the cathode is patterned and etched to form protruding nanostructures using a standard lithographic process. Various methods for fabricating these structures are provided, all of which are compatible with large-scale manufacturing. OLEDs made with these novel electrodes have greatly enhanced electron injection, have good environmental stability.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: December 4, 2012
    Assignee: The Regents of The University of California
    Inventors: Samuel S. Mao, Gao Liu, Stephen G. Johnson
  • ELECTRONICALLY CONDUCTIVE POLYMER BINDER FOR LITHIUM-ION BATTERY ELECTRODE
    Publication number: 20120119155
    Abstract: A family of carboxylic acid group containing fluorene/fluorenon copolymers is disclosed as binders of silicon particles in the fabrication of negative electrodes for use with lithium ion batteries. These binders enable the use of silicon as an electrode material as they significantly improve the cycle-ability of silicon by preventing electrode degradation over time. In particular, these polymers, which become conductive on first charge, bind to the silicon particles of the electrode, are flexible so as to better accommodate the expansion and contraction of the electrode during charge/discharge, and being conductive promote the flow battery current.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Gao Liu, Shidi Xun, Vincent S. Battaglia, Honghe Zheng
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120070440
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 22, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064083
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: June 30, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064068
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064067
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8133981
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 13, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8088898
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: January 3, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8008450
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Carbon nanotube polymer composition and devices
    Patent number: 7960037
    Abstract: A thin film device and compound having an anode, a cathode, and at least one light emitting layer between the anode and cathode, the at least one light emitting layer having at least one carbon nanotube and a conductive polymer.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: June 14, 2011
    Assignee: The Regents of the University of California
    Inventors: Gao Liu, Stephen Johnson, John B. Kerr, Andrew M. Minor, Samuel S. Mao
  • Single ion conductor cross-linked polymeric networks
    Patent number: 7902299
    Abstract: Single ion conductors comprising polymer electrolytes prepared by grafting a salt compound onto a comb-branch polymer or dendrimer are disclosed having superior properties.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: March 8, 2011
    Assignee: The Regents of the University of California
    Inventors: John Borland Kerr, Shanger Wang, Jun Hou, Steven Edward Sloop, Yong Bong Han, Gao Liu
  • RHO-KINASE INHIBITORS
    Publication number: 20100216789
    Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
    Type: Application
    Filed: January 15, 2010
    Publication date: August 26, 2010
    Inventors: Dhanapalan NAGARATHNAM, Uday Khire, Davoud Asgari, Jianxing Shao, Xiao-Gao Liu, Chunguang Wang, Barry Hart, Olaf Weber, Mark Lynch, Lei Zhang, Lei Wang
  • Biodegradable Synthetic Bone Composites
    Publication number: 20100179243
    Abstract: The invention provides for a biodegradable synthetic bone composition comprising a biodegradable hydrogel polymer scaffold comprising a plurality of hydrolytically unstable linkages, and an inorganic component; such as a biodegradable poly(hydroxyethylmethacrylate)/hydroxyapatite (pHEMA/HA) hydrogel composite possessing mineral content approximately that of human bone.
    Type: Application
    Filed: December 8, 2009
    Publication date: July 15, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Gao Liu, Dacheng Zhao, Eduardo Saiz, Antoni P. Tomsia